BioMarin Pharma (BMRN) Tops Q1 EPS by 39c, Revs Beat; Trims FY Rev Outlook

BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $0.44, $0.39 better than the analyst estimate of $0.05. Revenue for the quarter came in at $502.1 million versus the consensus estimate of $468.77 million.

GUIDANCE:

BioMarin Pharma sees FY2020 revenue of $1.85-1.95 billion, versus prior of $1.95-$2.05 billion and the consensus of $1.97 billion.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Ennis (EBF) Reports In-Line Q1 EPS
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance